[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"medullary-thyroid-carcinoma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:medullary-thyroid-carcinoma":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,42,71,98,121],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100638922","a-comparison-of-68gadotatate-and-18fambf3tate-for-the-staging-and-assessment-of-neuroendocrine-malignancies-100638922",false,"NCT07621146","A Comparison of [68Ga]DOTATATE and [18F]AmBF3TATE for the Staging and Assessment of Neuroendocrine Malignancies","A Prospective and Head-to-head Comparison of [68Ga] Ga-DOTATATE and [18F]AmBF3TATE for the Staging and Assessment of Neuroendocrine Malignancies: NET-COMPARE Study","NET-COMPARE","Inclusion Criteria:\n\n* Age ≥18 years\n* Patients referred for and meeting institutional criteria for a \\[68Ga\\]DOTATATE PET\u002FCT for the investigation of a known or suspected neuroendocrine malignancy (BC Cancer criteria APPENDIX A).\n\nExclusion Criteria:\n\n* Pregnant and breast-feeding patients.\n* Patients unwilling or unable to undergo a second PET\u002FCT.\n* Patients exceeding the safe weight limit of the scanner (204.5 kg) or who cannot fit through the PET\u002FCT bore (70cm diameter).","ALL","18 Years",{"count":20,"type":21},51,"ESTIMATED","OBSERVATIONAL","Neuroendocrine tumours (NETs) are generally slow growing, but some can be aggressive and resistant to treatment. Compared to healthy cells, the surface of these tumor cells has a greater number of molecules called somatostatin receptors (SSTR) which requires specific PET scan tracers to sufficiently capture on images. The current standard of care tracer at BC Cancer for SSTRs on NETs is 68Ga-DOTATATE. This project seeks to identify if 18F-AmBF3-TATE (a tracer that has established safety from phase 1 trial results), is comparable in disease detection, no. of lesions identified, image quality, safety and overall accuracy, to 68Ga-DOTATATE.",[25,26,27,28],"Neuroendocrine Tumors, NET","Pheochromocytoma\u002FParaganglioma","SSTR-expressing Tumors","Medullary Thyroid Carcinoma","NOT_YET_RECRUITING","2026-05-27",{"date":32,"type":33},"2026-06-02","ACTUAL",{"date":35,"type":21},"2026-09-15",{"date":37,"type":21},"2028-03",{"name":39,"class":40},"British Columbia Cancer Agency","OTHER",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":48,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":50,"targetDuration":4,"studyType":52,"phases":53,"briefSummary":55,"conditions":56,"keywords":57,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":41},"100622409","phase-3-ctr-fapi-guided-precision-surgery-for-newly-diagnosed-mtc-100622409","NCT07383246","CTR-FAPI-guided Precision Surgery for Newly Diagnosed MTC","68Ga-CTR-FAPI PET-CT-guided Precision Surgery for Newly Diagnosed Medullary Thyroid Carcinoma: A Multicenter, Open-labeled, Randomized Controlled Phase 3 Trial","CAST-MTC","Inclusion Criteria:\n\n* Newly-diagnosed medullary thyroid carcinoma meeting either criterion a or criteria b + c:\n\n  1. Pathologically or cytologically confirmed diagnosis;\n  2. Elevated serum calcitonin level (\\>10 pg\u002FmL);\n  3. Other infectious or neoplastic diseases excluded.\n* Life expectancy ≥ 12 weeks;\n* ECOG performance status of 0 or 1;\n* Absence of distant metastasis confirmed by conventional imaging, with resectable locoregional disease;\n* Scheduled to undergo surgery within 30 days;\n* Females of childbearing potential must use effective contraception (e.g., sterilization, intrauterine device, condoms, oral\u002Finjectable contraceptives, abstinence, or partner vasectomy) during the study and for 6 months after study completion. Male participants must agree to use effective contraception during the same period;\n* Capable of understanding and voluntarily signing the informed consent form with good compliance.\n\nExclusion Criteria:\n\n* History of prior treatment for medullary thyroid carcinoma (e.g., surgery, radiotherapy, targeted therapy, radionuclide therapy, or interventional therapy).\n* Major organ dysfunction, defined as:\n\n  1. Bone marrow impairment: WBC ≤ 4.0×10⁹\u002FL or neutrophils ≤ 1.5×10⁹\u002FL; platelets ≤ 100×10⁹\u002FL; hemoglobin ≤ 90 g\u002FL\n  2. Hepatic impairment: PT or APTT ≥ 1.5 × ULN; total bilirubin ≥ 1.5 × ULN; ALT\u002FAST ≥ 2.5 × ULN (or ≥ 5 × ULN in participants with liver metastases); ALP ≥ 2.5 × ULN (or ≥ 4.5 × ULN in cases with bone or liver metastases)\n  3. Renal impairment: BUN ≥ 1.5 × ULN; serum creatinine ≥ 1.5 × ULN\n* Women who are planning pregnancy, currently pregnant, or breastfeeding.\n* History of other malignant tumors;\n* Inability to lie flat for at least 30 minutes;\n* Known allergy to contrast agents;\n* Claustrophobia or other psychiatric disorders that may preclude compliance with study procedures;\n* Unwillingness to participate in the clinical trial;\n* Assessed as not being a surgical candidate or refusal to undergo surgery;\n* Any other condition deemed by the investigator to make the participant unsuitable for the study.",{"count":51,"type":21},150,"INTERVENTIONAL",[54],"PHASE3","This is a multicenter, randomized, open-label, non-inferiority Phase III clinical trial, aims to compare 68Ga-CTR-FAPI PET-CT-guided surgery to investigator-chosen surgical approaches to evaluate its efficacy in treating newly diagnosed medullary thyroid carcinoma. This study plans to enroll 150 newly diagnosed MTC patients, who will be randomly assigned in a 2:1 ratio to the experimental group (surgery based on 68Ga-CTR-FAPI PET-CT findings) and the control group (surgery based on the investigator's choice). The primary endpoint is the biochemical cure rate, with secondary endpoints including the biochemical cure rate in the R0 resection subgroup, the unnecessary dissection rate in the biochemical-cured subgroup, 3-year recurrence-free survival, the rate of change in surgical extent, and diagnostic accuracy.",[28],[58,59,60],"Medullary Thyroid Cariconma","Surgery","CTR-FAPI","RECRUITING","2026-01-26",{"date":64,"type":33},"2026-02-03",{"date":66,"type":33},"2025-08-25",{"date":68,"type":21},"2031-12-31",{"name":70,"class":40},"Cancer Institute and Hospital, Chinese Academy of Medical Sciences",{"id":72,"slug":73,"hasResults":11,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":4,"eligibilityCriteria":77,"healthyVolunteers":78,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":79,"targetDuration":4,"studyType":52,"phases":81,"briefSummary":83,"conditions":84,"keywords":85,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":41},"100603607","research-on-the-application-of-68ga-dota-cck-fs-petct-in-mtc-100603607","NCT07138716","Research on the Application of 68Ga-DOTA-CCK-FS PET\u002FCT in MTC","Application Study of 68Ga-DOTA-CCK-FS PET\u002FCT in Medullary Thyroid Carcinoma (MTC) and Various Other Tumors With Positive Expression of Cholecystokinin-2 Receptor (CCK-2R)","Inclusion Criteria:\n\n1. Age not limited (male or female).\n2. Diagnosis:Confirmed or suspected medullary thyroid carcinoma (MTC) based on:\n\n   Fine-needle aspiration (FNA) cytology\u002Fhistopathology, or Elevated serum calcitonin\u002FCEA with thyroid nodule(s), or Clinical\u002Fhereditary suspicion (e.g., MEN2 syndrome), or Other histologically confirmed CCK-2R-positive tumors (e.g., neuroendocrine tumors, gastric\u002Fovarian cancers).\n3. Performance Status: Life expectancy ≥12 weeks.\n4. Contraception: Willingness to use effective birth control (if applicable).\n5. Consent: Signed informed consent and compliance with follow-up.\n\nExclusion Criteria:\n\n1. Severe hepatic\u002Frenal dysfunction (e.g., ALT\u002FAST \\>3×ULN, Cr \\>2.0 mg\u002FdL).\n2. Pregnancy\u002Flactation or planned pregnancy during the study.\n3. Inability to lie still for PET\u002FCT (e.g., severe claustrophobia).\n4. Concurrent conditions compromising study safety (investigator's judgment).\n\n\\*Note: CCK-2R positivity may be confirmed via prior immunohistochemistry (if available) or inferred from tumor type (e.g., MTC).\\*",true,{"count":80,"type":21},30,[82],"NA","This study explores the clinical application of 68Ga-DOTA-CCK-FS PET\u002FCT in detecting cholecystokinin-2 receptor (CCK-2R)-positive tumors, particularly medullary thyroid cancer (MTC) and other malignancies. Led by Prof. Luo Yaping (PUMCH Nuclear Medicine) and Prof. Liu Zhibo (Peking University, radiochemistry expert), the trial will enroll 30-40 patients to compare 68Ga-DOTA-CCK-FS imaging with standard PET\u002FCT (e.g., 18F-FDG or 68Ga-DOTATATE). The novel tracer shows higher tumor uptake and retention in preclinical studies, potentially improving diagnosis and treatment guidance for aggressive, CCK-2R-expressing cancers. The study leverages PUMCH's Class IV Radioactive Drug License for advanced radiopharmaceutical development. Risks are minimal (diagnostic radiation dose only), and participants receive free imaging assessments. Results aim to refine precision diagnostics for MTC and related tumors.",[28],[86,87,88],"MTC","CCK-2R","PET\u002FCT","2025-08-22",{"date":91,"type":33},"2025-08-24",{"date":93,"type":33},"2025-05-10",{"date":95,"type":21},"2028-12-01",{"name":97,"class":40},"Luo Yaping",{"id":99,"slug":100,"hasResults":11,"nctId":101,"briefTitle":102,"officialTitle":103,"acronym":4,"eligibilityCriteria":104,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":105,"enrollmentInfo":106,"targetDuration":4,"studyType":52,"phases":108,"briefSummary":110,"conditions":111,"keywords":4,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":112,"lastUpdatePostDateStruct":113,"startDateStruct":115,"completionDateStruct":117,"leadSponsor":119,"locationsCount":41},"100556071","phase-1-head-to-head-study-of-68ga-mgs5-versus-68ga-dotatate-petct-in-patients-with-medullary-thyroid-carcinoma-100556071","NCT06520319","Head-to-head Study of 68Ga-MGS5 Versus 68Ga-DOTATATE PET\u002FCT in Patients With Medullary Thyroid Carcinoma","Head-to-head Study of 68Ga-MGS5 Versus 68Ga-DOTATATE PET\u002FCT in Patients With Medullary Thyroid Carcinoma: a Prospective Study","Inclusion Criteria:\n\n* Patients of either gender, aged ≥ 18 years and ≤80 years.\n* Patients with pathologic findings confirming the diagnosis of MTC\n* Patients with MTC recurrence\n* Signed written consent\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding female patients\n* Patients with claustrophobic behavior\n* The inability or unwillingness of the research participant, parent or legal representative to provide written informed consent","80 Years",{"count":107,"type":21},20,[109],"PHASE1","Cholecystokinin-2 (CCK2) receptor is overexpressed in more than 90% of MTC cases, and preclinical studies have shown that 68Ga-MGS5 (targeting CCK2) has good stability in vivo and is promising for diagnosis and staging of MTC. This prospective study will compare the diagnostic effects of 68Ga-MGS5 and 68Ga-DOTATATE on MTC primary foci, lymph node metastasis, and distant metastasis, and explore the effect of 68Ga-MGS5 PET\u002FCT on the clinical staging (TNM staging) of MTC.",[28],"2024-07-21",{"date":114,"type":33},"2024-07-25",{"date":116,"type":33},"2023-06-21",{"date":118,"type":21},"2025-07",{"name":120,"class":40},"First Affiliated Hospital of Fujian Medical University",{"id":122,"slug":123,"hasResults":11,"nctId":124,"briefTitle":125,"officialTitle":126,"acronym":4,"eligibilityCriteria":127,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":128,"targetDuration":4,"studyType":52,"phases":130,"briefSummary":132,"conditions":133,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":137,"lastUpdatePostDateStruct":138,"startDateStruct":140,"completionDateStruct":142,"leadSponsor":144,"locationsCount":4},"100525402","phase-2-trial-of-lu-177-dotatate-lutathera-in-unlicensed-indications-100525402","NCT06121271","Trial of Lu-177 DOTATATE (Lutathera®) in Unlicensed Indications","Trial of Lu-177 DOTATATE (Lutathera®) in Unlicensed Indications Including Bronchial and Thymic Neuroendocrine Tumour, Paraganglioma\u002FPhaeochromocytoma, Medullary Thyroid Carcinoma, and Repeat Peptide Receptor Radionuclide Therapy","Inclusion Criteria:\n\n1. Patients ≥18 years of age.\n2. Participants capable of giving informed consent\n3. Presence of unresectable or metastatic, well differentiated, somatostatin receptor positive non gastroenteropancreatic neuroendocrine tumours. Or for those having 2 cycles repeat therapy, GEP NET \\> 18 months from start of previous PRRT.\n4. Patients must have progressive disease based on RECIST Criteria, Version 1.1. In order to make the assessment, two CT (or MRI) scans are required. The oldest scan must not be older than 3 years from the date of enrolment. The most recent scan must not be older than 6 weeks from the date of enrolment.\n5. Confirmed presence of somatostatin receptors on all target lesions (for target\u002Fnon-target\u002Fmeasurable lesions definition see RECIST Criteria, Version 1.1) documented by CT\u002FMRI scans, based on positive OctreoScan or Ga68 Dotatate PET imaging within 24 weeks prior to enrolment in the trial.\n6. The tumour uptake observed in each target lesion (for target\u002Fnon-target\u002Fmeasurable lesions definition see RECIST Criteria, Version 1.1) using OctreoScan\u002FTc-99m-SRS should be ≥ normal liver uptake observed on planar imaging.\n7. The tumour uptake observed in each target lesion (for target\u002Fnon-target\u002F measurable lesions definition see RECIST Criteria, Version 1.1) using Ga68 Dotatate PET should be ≥ normal liver uptake observed on PET imaging.\n8. KPS ≥60.\n9. Presence of at least 1 measurable site of disease on cross-sectional imaging.\n10. Females of childbearing potential (defined as \\\u003C2 years after last menstruation and not surgically sterile) and males, who are not surgically sterile or with female partners of childbearing potential must be willing to use a highly effective method of contraception during treatment and for a minimum of 6 months after the end of treatment (hormonal or barrier method of birth control; abstinence). Contraceptive methods that can achieve a failure rate of less than 1% per year when used consistently and correctly are considered as highly effective birth control methods. Such methods include:\n\n    • combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation:\n    * oral\n    * intravaginal\n    * transdermal\n\n      * progestogen-only hormonal contraception associated with inhibition of ovulation\n    * oral\n    * injectable\n    * implantable\n\n      • intrauterine device (IUD)\n\n      • intrauterine hormone-releasing system (IUS)\n\n      • bilateral tubal occlusion\n\n      • vasectomised partner\n\n      • sexual abstinence\n      * Women of childbearing potential (WOCBP) must have a negative pregnancy test within 7 days prior to treatment initiation). NOTE: Participants are considered not of childbearing potential if they are surgically sterile (i.e. they have undergone a hysterectomy, bilateral tubal ligation or bilateral oophorectomy) or they are postmenopausal. Inclusion Criteria for Subsequent Treatments\n\n1\\. Both serum creatinine ≤150 μmol\u002FL (≤1.7 mg\u002FdL) and calculated creatinine clearance ≥40 mL\u002Fmin, eventually confirmed by measured creatinine clearance (or measured GFR) using isotopic GFR measurement ≥40 mL\u002Fmin (the measured creatinine clearance\u002FGFR is required only as confirmatory exam).\n\n2\\. Haemoglobin concentration ≥5.0 mmol\u002FL (≥8.0 g\u002FdL); WBC ≥2 x109\u002FL (≥2000\u002Fmm3); platelets ≥75 x109\u002FL (≥75 x103\u002Fmm3).\n\n3\\. Total bilirubin ≤3x ULN. 4. Serum albumin \\>3.0 g\u002FdL, or serum albumin ≤3.0 g\u002FdL, but normal prothrombin time.\n\n5\\. KPS ≥60.\n\nExclusion Criteria:\n\n* Participants will not be eligible for trial participation if they meet any of the exclusion criteria, or will be discontinued at the discretion of the Investigator if they develop any of the exclusion criteria during the trial.\n\nExclusion Criteria at Baseline\n\n1. Either serum creatinine \\>150 μmol\u002FL (\\>1.7 mg\u002FdL), or calculated creatinine clearance \\\u003C40 mL\u002Fmin, eventually confirmed by measured creatinine clearance (or measured GFR using isotopic GFR measurement) \\\u003C40 mL\u002Fmin (the measured creatinine clearance\u002FGFR is required only as confirmatory exam).\n2. Haemoglobin concentration \\\u003C5.0 mmol\u002FL (\\\u003C8.0 g\u002FdL); WBC \\\u003C2 x109\u002FL (2000\u002Fmm3); platelets \\\u003C75 x109\u002FL (75 x103\u002Fmm3).\n3. Total bilirubin \\>3x upper limit of normal (ULN).\n4. Serum albumin \\\u003C3.0 g\u002FdL unless prothrombin time is within the normal range.\n5. Pregnancy, planning a pregnancy or lactation.\n6. Any surgery, radioembolization, chemoembolization, chemotherapy, and radiofrequency ablation within 12 weeks prior to enrolment in the trial.\n7. Interferon, Everolimus (mTOR-inhibitors), or other systemic therapies within 4 weeks prior to enrolment in the trial.\n8. Patients with a history of brain metastases must have a head CT with contrast to document stable disease prior to enrolment in the trial.\n9. Uncontrolled congestive heart failure (NYHA II, III, IV).\n10. Uncontrolled diabetes mellitus as defined by a fasting blood glucose \\>2x ULN.\n11. Any participant receiving treatment with short-acting Octreotide, which cannot be interrupted for 12 hours before and 24 hours after the administration of Lutathera, or any participant receiving treatment with Octreotide LAR or Lanreotide Autogel, which cannot be interrupted for at least 28 days before the administration of Lutathera, unless the tumour uptake observed on target and non-target but measurable lesions by OctreoScan or Ga68 Dotatate PET imaging during continued Octreotide LAR or Lanreotide Autogel treatment is at least as high as normal liver uptake observed by planar imaging (Kwekkeboom, Krenning et al. 2009).\n12. Patients with any other significant medical, psychiatric, or surgical condition, currently uncontrolled by treatment, which may interfere with completion of the trial.\n13. Prior external beam radiation therapy to more than 25% of the bone marrow.\n14. Current spontaneous urinary incontinence.\n15. Other known co-existing malignancies except non-melanoma skin cancer and carcinoma in situ of the uterine cervix, unless definitively treated and proven no evidence of recurrence for 5 years.\n16. Patients who have not provided a signed ICF to participate in the trial, obtained prior to the start of any protocol related activities.\n17. Patient with known incompatibility to CT Scans with IV contrast due to allergic reaction or renal insufficiency. If such participants can be imaged without the use of CT contrast material (ie, can tolerate MRI scans), such participants would not be excluded.\n18. Patients who have participated in any therapeutic clinical trial\u002Freceived any investigational agent within the last 30 days are excluded from participation in this trial.\n19. Patients with hypersensitivity to Lutathera (active substance or any of the excipients).\n20. Involved in the planning or conduct of this trial.\n21. Unwilling or unlikely to comply with the requirements of the trial. Exclusion Criteria for Subsequent Treatments\n\n1\\. Exclusion criteria for Baseline # 1, 2, 3, 4, and 10 apply to all subsequent treatments, when a relationship cannot be excluded with either trial drugs or the corresponding toxicity has not resolved.\n\n2\\. In relation to renal function, participants are also excluded from further therapy in case of \\>40% increase of serum creatinine over the baseline and with a concomitant decrease of \\>40% in creatinine clearance as calculated according to the Cockroft-Gault method, eventually confirmed by measured creatinine clearance (or GFR), if a relationship may not be excluded and the corresponding toxicity has not resolved.\n\n3\\. When such exclusion criteria events occur, the participant will postpone any subsequent trial treatment until resolution of the event (normalisation or return to baseline values). The participant remains in the trial and continues observation with the scheduled tumour and clinical assessments.\n\n4\\. All other exclusion criteria for enrolment eligibility apply to all subsequent treatments.",{"count":129,"type":21},110,[131],"PHASE2","This study is a phase 2, open, single-site trial. The primary objective of this study is to prospectively evaluate the safety and efficacy in participants treated with Lu-177 DOTATATE (Lutathera) in unresectable or metastatic, somatostatin receptor-expressing neuroendocrine tumours (NET) in currently unlicensed indications (eg, bronchial and thymic NET; paraganglioma\u002Fphaeochromocytoma; medullary thyroid carcinoma; and those requiring repeat peptide receptor radionuclide therapy (PRRT) with 2 further cycles of Lutathera). The aim is to recruit a total of 75-110 participants. Each patient will receive 4 cycles of Lutathera with 8-12 weeks time interval (except patients requiring repeat PRRT will receive 2 further cycles of Lutathera). The follow-up period will be for 2 years from the date of the last treatment.",[134,135,28,136],"Bronchial and Thymic Neuroendocrine Tumour","Paraganglioma\u002F Phaeochromocytoma","Those Requiring Repeat Peptide Receptor Radionuclide Therapy","2023-11-30",{"date":139,"type":33},"2023-12-07",{"date":141,"type":21},"2023-12-18",{"date":143,"type":21},"2027-11-06",{"name":145,"class":40},"University College, London"]